King's College London

NICE recommends LYTENAVA™ (bevacizumab gamma) for wet AMD treatment, marking the first positive reimbursement decision worldwide. LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for wet AMD in the EU and UK, with a planned launch in H1 2025. The decision is expected to benefit 40,000 new wet AMD patients annually in the UK.

A study published in The Lancet Respiratory Medicine suggests benralizumab, an injection, may be a breakthrough treatment for asthma and COPD flare-ups, reducing treatment failure rates and side-effects compared to steroids. The trial showed 45% treatment failure with benralizumab versus 74% with prednisolone, with faster symptom recovery and improved quality of life. Phase 3 trials are needed for approval.

The 'Nuclear Imaging Equipment Pipeline Report, 2024 Update' provides comprehensive details on pipeline products, clinical trials, and key companies involved in nuclear imaging equipment development, aiding strategic R&D, market entry, and mergers and acquisitions.

A phase 2 clinical trial ABRA, led by King's College London and sponsored by the University of Oxford, found that repurposing the drug Benralizumab, a monoclonal antibody targeting eosinophils, can reduce the need for further treatment and hospitalizations in asthma and COPD exacerbations. A single dose injected at the point of exacerbation was more effective than steroid tablets, potentially revolutionizing asthma and COPD care.

AstraZeneca's benralizumab, an IL-5 inhibitor, shows promise in treating acute asthma attacks, potentially revolutionizing care for severe exacerbations. A study by King's College London found benralizumab, used with prednisolone, reduced treatment failure rates from 74% to 45% in patients with high eosinophil levels. This marks a significant advance in asthma treatment.

New treatment benralizumab for asthma and COPD, developed by AstraZeneca, shows significant improvements in respiratory symptoms and reduced treatment failures compared to steroids, with fewer side effects. This marks the first new treatment in 50 years.

Scientists discover Benralizumab, a new asthma treatment targeting eosinophils, offering a more precise approach than traditional steroids, with significant improvements in clinical trials.

A new drug, Benralizumab, targets specific white blood cells to reduce lung inflammation, proving more effective than steroids in treating asthma and COPD, leading to fewer treatment failures and hospital visits. The treatment can be administered at home or in a GP practice.

Benralizumab, a monoclonal antibody, was found more effective than steroids in treating eosinophilic exacerbations of asthma and COPD, reducing hospitalizations and improving quality of life in a phase two clinical trial.

A new treatment for severe asthma and COPD attacks, an injection, has been found more effective than steroid tablets, reducing further treatment needs by 30%, marking the first breakthrough in 50 years.